Nykode Therapeutics Dirección

Dirección controles de criterios 1/4

El CEO de Nykode Therapeutics es Michael Engsig, nombrado en Sep 2019, tiene una permanencia de 5.17 años. posee directamente un 0.005% de las acciones de la empresa, con un valor de NOK43.05K. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 2.5 años, respectivamente.

Información clave

Michael Engsig

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	5.2yrs
Participación del CEO	0.005%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	2.5yrs

Actualizaciones recientes de la dirección

Recent updates

We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate

Aug 05

Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Mar 02

Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)

Jan 22

We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth

Aug 20

Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business

Apr 06

Could The Vaccibody AS (OB:VACC) Ownership Structure Tell Us Something Useful?

Jan 25

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Michael Engsig en comparación con los beneficios de Nykode Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$38m
Mar 31 2024	n/a	n/a	-US$40m
Dec 31 2023	n/a	n/a	-US$35m
Sep 30 2023	n/a	n/a	-US$42m
Jun 30 2023	n/a	n/a	-US$47m
Mar 31 2023	n/a	n/a	-US$46m
Dec 31 2022	n/a	n/a	-US$43m
Sep 30 2022	n/a	n/a	-US$20m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$10m
Dec 31 2021	US$567k	US$330k	-US$9m
Sep 30 2021	n/a	n/a	US$147m
Jun 30 2021	n/a	n/a	US$146m
Mar 31 2021	n/a	n/a	US$146m
Dec 31 2020	US$424k	US$280k	US$150m
Sep 30 2020	n/a	n/a	-US$24m
Jun 30 2020	n/a	n/a	-US$19m
Mar 31 2020	n/a	n/a	-US$15m
Dec 31 2019	US$113k	US$106k	-US$14m

Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Michael es razonable en comparación con empresas de tamaño similar en el mercado Norwegian.

Compensación vs. Ingresos: La compensación de Michael ha aumentado mientras la empresa no es rentable.

CEO

Michael Engsig (52 yo)

5.2yrs

Permanencia

US$567,000

Compensación

Mr. Michael Thyring Engsig is an Independent Director at FluoGuide A/S since March 21, 2023. He has been Chief Executive Officer of Nykode Therapeutics AS (formerly known as Vaccibody AS) since September 1...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Michael Engsig	Chief Executive Officer	5.2yrs	US$567.00k	0.0049% NOK 43.0k
Harald Gurvin	Chief Financial Officer	3.5yrs	sin datos	0.0092% NOK 81.6k
Ulrich Blaschke	Chief Technology Officer	less than a year	sin datos	sin datos
Agnete Fredriksen	Chief Scientific Officer & Business Development	no data	sin datos	sin datos
Louise Stubbe	Chief Legal Officer	2.8yrs	sin datos	sin datos
Klaus Edvardsen	Chief Research & Development Officer	2.3yrs	sin datos	sin datos

2.8yrs

Permanencia media

50.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de NYKD se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Bernd Seizinger	Director	10.8yrs	US$53.00k	0.20% NOK 1.8m
Einar Greve	Deputy Board Member	2.5yrs	US$45.00k	0.54% NOK 4.8m
Alf Gunnar Nicklasson	Chairman of the Board	no data	US$95.00k	0.043% NOK 386.0k
Trygve Lauvdal	Observer to the Board	no data	US$13.00k	sin datos
Christian Åbyholm	Director	4.8yrs	US$50.00k	0.66% NOK 5.9m
Anne Michelle Whitaker	Director	2.5yrs	US$50.00k	sin datos
Birgitte Volck	Director	3.5yrs	US$53.00k	0.0062% NOK 55.2k
Elaine Sullivan	Director	2.5yrs	US$60.00k	sin datos
Harald Arnet	Director	1.5yrs	US$50.00k	0.051% NOK 456.6k

2.5yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de NYKD no se considera experimentada (2.5 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Nykode Therapeutics Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Chairman of the Board recently bought kr283k worth of stock

Director recently bought kr310k worth of stock

Chief Executive Officer recently bought kr100k worth of stock

Nykode Therapeutics AS Announces Management Changes

Director exercised options and sold kr7.4m worth of stock

No independent directors

Recent updates

Price target decreased by 21% to kr22.00

New minor risk - Market cap size

Nykode Therapeutics ASA Announces Updates on its Inverse Vaccine Platform at Pegs Europe

Consensus revenue estimates decrease by 19%

Price target decreased by 20% to kr29.13

Consensus revenue estimates decrease by 54%, EPS upgraded

Chairman of the Board recently bought kr283k worth of stock

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate

New minor risk - Share price stability

Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting

Consensus revenue estimates decrease by 35%, EPS upgraded

Consensus revenue estimates increase by 37%, EPS downgraded

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer

Director recently bought kr310k worth of stock

Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer

Nykode Therapeutics ASA Announces Advances in the Inverse Vaccine Platform with the Potential to Treat Autoimmune Diseases

Price target decreased by 36% to kr43.00

Consensus EPS estimates upgraded to US$0.18 loss

Chief Executive Officer recently bought kr100k worth of stock

Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)

Nykode Therapeutics AS to Report Q4, 2024 Results on Feb 26, 2025

Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer

Third quarter 2023 earnings released: US$0.03 loss per share (vs US$0.05 loss in 3Q 2022)

New minor risk - Shareholder dilution

Nykode Therapeutics ASA Initiates Phase 1/2a Trial of VB10.16 in First Line HPV16-Positive Head and Neck Cancer

Nykode Therapeutics ASA Announces Advances in Clinical Pipeline and Research

Nykode Therapeutics ASA Announces FDA Approval of IND for VB-C-04, a Trial of VB-C-04 in HPV16-Positive Cervical Cancer

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth

Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the Next Trial in Advanced Cervical Cancer

Nykode Therapeutics AS Announces Management Changes

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business

Full year 2022 earnings released: US$0.15 loss per share (vs US$0.033 loss in FY 2021)

Director exercised options and sold kr7.4m worth of stock

Nykode Therapeutics AS to Report Q3, 2023 Results on Nov 15, 2023

Nykode Expands Clinical Development Plan for Its Lead Cancer Vaccine Vb10.16 in Hpv16-Positive Cancers

Third quarter 2022 earnings released: US$0.05 loss per share (vs US$0.03 loss in 3Q 2021)

No independent directors

Nykode Therapeutics Presents Additional Efficacy Analysis in Phase 2 Study of VB10.16 in Combination with Atezolizumab in Advanced Cervical Cancer

Nykode Therapeutics ASA Announces Presentation of Positive Immunogenicity Results from Phase 1/2A Study of VB10.NEO

Nykode Therapeutics ASA Announces Positive Results from the Phase 1/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate

Second quarter 2022 earnings released: US$0.03 loss per share (vs US$0.02 loss in 2Q 2021)

Nykode Therapeutics Announces Positive Interim Results in HPV+ Cervical Cancer Phase 2 Trial

Nykode Therapeutics AS Appoints Klaus Edvardsen as Chief Development Officer, Effective from July 1, 2022

Chairman of the Board recently bought kr321k worth of stock

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Nykode Therapeutics AS Appoints Elaine Sullivan and Anne Whitaker to the Board of Directors

Nykode Therapeutics AS Announces Positive Interim Results from Its Phase 2 Trial with VB10.16 in Combination with Immune Checkpoint Inhibitor Atezolizumab in Advanced Cervical Cancer

No independent directors

Nykode Therapeutics as Announces Presentation of Preclinical Data from Its Second Generation Vaccibody Vaccine Technology At 2022 American Association for Cancer Research (AACR) Annual Meeting

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Nykode Therapeutics Announces Completion of Patient Enrollment in Its Phase 2 Trial of Vb10.16 in Combination with Atezolizumab for the Treatment of Advanced Cervical Cancer

Investor sentiment deteriorated over the past week

Nykode Therapeutics AS Announces First Subject Dosed with Its T Cell Focused Next-Generation SARS-CoV-2 Vaccine Candidate

Director recently bought kr26m worth of stock

Nykode Therapeutics Announces Phase 1/2 Clinical Trial With Next Generation DNA-Based COVID-19 Vaccine Candidates

Key Executive recently sold kr21m worth of stock

Vaccibody AS announced that it expects to receive NOK 178.305538 million in funding from Regeneron Pharmaceuticals, Inc.

Investor sentiment improved over the past week

Third quarter 2021 earnings released: US$0.03 loss per share (vs US$0.017 loss in 3Q 2020)

Director recently sold kr112m worth of stock